AbCellera Biologics Inc. Common Shares

Day range

$12.05 – $12.95

Open

$12.70

Prev close

$12.46

Volume

2.11M

Market cap

$4.07B

Shares out

306.61M

P/E

—

P/S

61.50

P/B

4.54

P/FCF

—

ROE

-18.4%

ROA

-12.6%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 10, 2026

• Quarterly earningsNov 9, 2026

  On November 9, 2026, AbCellera Biologics Inc. (the "Company"), issued a press release announcing its financial and operational results for the quarter ended September 30, 2026.

• Public offeringAug 13, 2026

  On August 12, 2026, AbCellera Biologics Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC and J.P. Morgan Securities LLC as the representatives of the several underwriters (the "Underwriters") relating to an underwritten public offering of (a) 17,435,897 shares (the "Shares") of the Company's common shares, no par value per share (the "Common Shares") at a price to the public of $9.75 per Share, and (b) in lieu of Shares to certain investors, pre-funded warrants to purchase up to 3,076,926 Common Shares (the "Pre-Funded Warrants", and such Common Shares issuable upon the exercise of the Pre-Funded Warrants, the "Warrant Shares") at a price to the public of $9.74999 per Pre-Funded Warrant.

• Clinical trial resultsAug 10, 2026

  On August 10, 2026, AbCellera Biologics Inc. (the "Company") issued a press release announcing positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody

• Investor presentationAug 5, 2026

  In connection with its earnings call on August 5, 2026, to discuss its results for the quarter ended June 30, 2026, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.

• Partnership or collaborationJul 29, 2026

  On July 29, 2026, AbCellera Biologics Inc. (the "Company") issued a press release announcing a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. The Company will leverage its proprietary TCE platform to lead discovery and early development activities.

Days to cover

8.5

Short interest

29.02M

Avg volume

3.42M

As of Oct 30, 2026 · reported to FINRA twice monthly.

• AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
  positiveZacks Investment Research· Nov 9, 2026
• Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
  positiveZacks Investment Research· Nov 3, 2026
• Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
  neutralZacks Investment Research· Oct 12, 2026
• Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera
  positiveGlobeNewswire Inc.· Oct 12, 2026
• Prelude Cuts Q2 Losses and Costs 13%
  neutralThe Motley Fool· Aug 14, 2025